DexCom DXCM · NASDAQ
$86.04 -1.90% (-$1.67)
Summary
82 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 38% a year over the last 3 years.
- Out of every 100 USD of revenue, 20 USD is left as net profit.
- It earns 22 USD a year on every 100 USD of invested capital.
- Analysts expect revenue to grow by 12% this fiscal year.
What to watch
- The share price is above the Bulios Fair Price.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 33.1 USD for 1 USD of yearly profit. Over the last five years it was 118.5 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 19% a year over 5 years. Over the last 3 years it grew by 17% a year. For the next fiscal year analysts expect revenue to grow by 12%.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 38 USD
- Research and development 12 USD
- Sales and administration 27 USD
- Taxes and other 2.8 USD
- Net profit 20 USD
Net profit, industry median (Medical - Devices) 7.0 USD
Out of every 100 USD of revenue, 20 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 42
- Hold 8
- Sell 2
Today's price within the analysts' price targets
The average target of $91.43 is 6.3% above today's price. 81% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
The company reports no revenue by product.
By region
- Non-US 100%
Non-US brings in 100% of revenue.
Segments in detail